Other

Applied Medical Technologies, Inc.

Rockwell Medical, Inc.

Gupta, Ajay

Charak LLC

Ajay Gupta

Robert Chioini

Kate Chander Chiang

Carrie Guss

Vivian H Lin

The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPrfor prostaglandin Dand TPr for thromboxane Aand a pharmaceutically acceptable carrier.

Dual antagonist of PGD/DPr2 and Thromboxane A/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis

A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.

Solid soluble ferric pyrophosphate formulations, kits, and methods using the same

Bioavailable iron-containing parenteral nutrition compositions are provided that are physico-chemically stable. Iron is present in the form of soluble ferric pyrophosphate. Methods of preparation and use of the compositions are provide, as well as kits.

Parenteral nutrition composition containing iron

The present invention relates to oral compositions which are useful for nutrient supplementation. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of patients in various stages of chronic kidney disease and supplementing levels of physiological anti-oxidants, vitamins, and minerals in subjects requiring dialysis therapy.

Multivitamin and mineral compositions for individuals having renal disease

A pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate repletion may be in either liquid or solid form and may be usable as or usable for preparing a hemodialysis or peritoneal dialysis solution containing a pyrophosphate compound present in an amount that provides a concentration in the dialysis solution equivalent to an inorganic phosphorus concentration of at least 0.5 mg per deciliter.

Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion

Phosphate depletion, a physiological condition commonly seen in certain patient populations, including alcoholics, malnourished, acutely ill patients, patients receiving parenteral nutrition, patients being re-fed after prolonged fasting, and dialysis patients, requires intravenous supplementation when oral repletion is not feasible. This invention provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate, instead of phosphate, for phosphate or pyrophosphate repletion. During hemodialysis or peritoneal dialysis significant removal of phosphate and pyrophosphate occurs. Pyrophosphate depletion predisposes patients to vascular calcification. This invention further provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate or pyrophosphate repletion by addition of pyrophosphate to hemodialysis or peritoneal dialysis solutions.

A combination electronic communication and medical diagnostic apparatus includes a first component for transmitting or receiving a remote communication signal and a second component for generating vibration to be used in a medical diagnosis. The apparatus functions as a beeper/pager or cellular phone, as well as a medical diagnostic tool to detect and/or monitor neuropathy.

Method and combination electronic communication and medical diagnostic apparatus for detecting/monitoring neuropathy

A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.

Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients

A method of replacing iron losses during dialysis of patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis solutions, during dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidial ferric compound, preferably ferric pyrophosphate.

Method and pharmaceutical composition for replacing iron losses in dialysis patients

The invention relates to methods and compositions for the prevention and treatment of vitamin and other nutrient deficiencies in hemodialysis and peritoneal dialysis patients. Patients are dialyzed with a dialysate solution comprising at least one vitamin.

Growing community of inventors

Cerritos, CA, United States of America

Ajay Gupta